Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors

Merestinib is an oral multi-kinase inhibitor targeting a limited number of oncokinases including MET, AXL, RON and MKNK1/2. Here, we report that merestinib inhibits neurotrophic receptor tyrosine kinases NTRK1/2/3 which are oncogenic drivers in tumors bearing NTRK fusion resulting from chromosomal r...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Konicek, Bruce W., Capen, Andrew R., Credille, Kelly M., Ebert, Philip J., Falcon, Beverly L., Heady, Gary L., Patel, Bharvin K.R., Peek, Victoria L., Stephens, Jennifer R., Stewart, Julie A., Stout, Stephanie L., Timm, David E., Um, Suzane L., Willard, Melinda D., Wulur, Isabella H., Zeng, Yi, Wang, Yong, Walgren, Richard A., Betty Yan, Sau-Chi
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2018
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5862616/
https://ncbi.nlm.nih.gov/pubmed/29568395
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24488
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars